PA8471201A1 - Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea - Google Patents

Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea

Info

Publication number
PA8471201A1
PA8471201A1 PA19998471201A PA8471201A PA8471201A1 PA 8471201 A1 PA8471201 A1 PA 8471201A1 PA 19998471201 A PA19998471201 A PA 19998471201A PA 8471201 A PA8471201 A PA 8471201A PA 8471201 A1 PA8471201 A1 PA 8471201A1
Authority
PA
Panama
Prior art keywords
compositions
parathyroid hormone
selective
combinations including
therapeutic combinations
Prior art date
Application number
PA19998471201A
Other languages
English (en)
Inventor
Hua Zhu Ke
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8471201A1 publication Critical patent/PA8471201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Abstract

ESTA INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS DE COMBINACIONES SINERGICAS Y A PROCEDIMIENTOS QUE COMPRENDEN (-)-CIS-6-FENIL-5- (4-(2-PIRROLIDIN-1-Il-ETOXI)-FENIL -5,6,7,8-TETRAHIDRONAFTALEN-2-OL, O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES Y HORMONA PARATIROIDEA, O UNO DE SUS FRAGMENTOS BIOLOGICAMENTE ACTIVOS, A PROCEDIMIENTOS PARA USAR DICHAS COMPOSICIONES Y A ESTUCHES QUE CONTIENEN DICHAS COMPOSICIONES. LAS COMPOSICIONES SON UTILES PARA TRATAR FRAGILIDAD MUSCULO ESQUELETICA, INCLUYENDO OSTEOPOROSIS, FRACTURA OSTEOPOROTICA, MASA OSEA REDUCIDA Y FRAGILIDAD.
PA19998471201A 1998-06-16 1999-04-29 Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea PA8471201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8947998P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
PA8471201A1 true PA8471201A1 (es) 2000-09-29

Family

ID=22217879

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998471201A PA8471201A1 (es) 1998-06-16 1999-04-29 Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea

Country Status (34)

Country Link
US (1) US6132774A (es)
EP (1) EP1094808A1 (es)
JP (1) JP2002518323A (es)
KR (1) KR20010052818A (es)
CN (1) CN1305373A (es)
AP (1) AP9901580A0 (es)
AR (1) AR018867A1 (es)
AU (1) AU3725999A (es)
BG (1) BG105125A (es)
BR (1) BR9911228A (es)
CA (1) CA2335078A1 (es)
CO (1) CO5070584A1 (es)
EA (1) EA200001199A1 (es)
GT (1) GT199900066A (es)
HN (1) HN1999000063A (es)
HR (1) HRP20000858A2 (es)
HU (1) HUP0102759A3 (es)
ID (1) ID26873A (es)
IL (1) IL139588A0 (es)
IS (1) IS5719A (es)
MA (1) MA26649A1 (es)
NO (1) NO20006313L (es)
NZ (1) NZ508039A (es)
OA (1) OA11566A (es)
PA (1) PA8471201A1 (es)
PE (1) PE20000644A1 (es)
PL (1) PL344982A1 (es)
SK (1) SK18922000A3 (es)
TN (1) TNSN99119A1 (es)
TR (1) TR200003567T2 (es)
UA (1) UA60367C2 (es)
WO (1) WO1999065482A1 (es)
YU (1) YU75800A (es)
ZA (1) ZA993972B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
US20030191096A1 (en) * 2002-04-03 2003-10-09 Leonard Thomas W. Method of hormonal therapy
AU2004293013B2 (en) 2003-11-19 2011-04-28 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
TW201043595A (en) * 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
DE102010027016A1 (de) 2010-07-09 2012-01-12 Universitätsklinikum Jena Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen
CN111067907A (zh) * 2018-10-18 2020-04-28 常州大学 孕激素在抑制血管内皮生长因子表达中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254595A (en) * 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
NZ508039A (en) 2003-03-28
EP1094808A1 (en) 2001-05-02
GT199900066A (es) 2000-10-31
CO5070584A1 (es) 2001-08-28
PL344982A1 (en) 2001-11-19
KR20010052818A (ko) 2001-06-25
JP2002518323A (ja) 2002-06-25
UA60367C2 (uk) 2003-10-15
ID26873A (id) 2001-02-15
CN1305373A (zh) 2001-07-25
NO20006313D0 (no) 2000-12-12
AP9901580A0 (en) 1999-06-30
MA26649A1 (fr) 2004-12-20
BR9911228A (pt) 2001-02-13
TR200003567T2 (tr) 2001-06-21
WO1999065482A1 (en) 1999-12-23
YU75800A (sh) 2003-12-31
IS5719A (is) 2000-11-21
AU3725999A (en) 2000-01-05
PE20000644A1 (es) 2000-08-02
HUP0102759A2 (hu) 2002-03-28
CA2335078A1 (en) 1999-12-23
NO20006313L (no) 2000-12-12
HRP20000858A2 (en) 2001-10-31
IL139588A0 (en) 2002-02-10
EA200001199A1 (ru) 2001-04-23
BG105125A (en) 2001-11-30
HUP0102759A3 (en) 2002-12-28
SK18922000A3 (sk) 2001-09-11
HN1999000063A (es) 2000-01-12
OA11566A (en) 2004-05-26
ZA993972B (en) 2000-12-15
US6132774A (en) 2000-10-17
AR018867A1 (es) 2001-12-12
TNSN99119A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
PA8471201A1 (es) Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
TR199800767T2 (xx) Proteaz engelleyicileri.
HN1999000210A (es) Composiciones de celecoxib
BR0111237B1 (pt) implante para um osso e aparelho osteosintÉtico para fixaÇço de um émero fraturado.
CO4890856A1 (es) CICATRIZACION DE FRACTURAS USANDO ANALOGOS DE PTHrP
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
GT199800158AA (es) Agonistas de prostaglandinas y su uso para tratar trastornos oseos
PA8484301A1 (es) Formulaciones farmaceuticas de liberacion controlada
NL300243I1 (nl) Proteïne formuleringen.
AR049876A1 (es) Composiciones farmaceuticas para tratar enfermedades de la piel que comprenden una combinacion de epinastina y uno o mas minerales adicionales o uno o mas farmacos brutos
EA200600228A1 (ru) Лечение нарушений костной ткани с использованием селективных модуляторов адрогенных рецепторов
BR0008509A (pt) Composição farmacêutica oral estabilizada contendo iodeto e iodato e método
AR044775A1 (es) Composiciones farmaceuticas de atorvastatina
ECSP044961A (es) Acido n-(5-clorosaliciloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides
DK1694660T3 (da) Fremgangsmåde til fremstilling af vandfri og hydrerede aktive farmaceutiske bestanddele (API's); stabile farmaceutiske sammensætninger fremstillet af disse og anvendelser af disse sammensætninger
PA8475901A1 (es) Terapia de combinacion para la fragilidad musculoesqueletica
BR0203267A (pt) Combinações farmacêuticas para o tratamento de doenças neurodegenerativas
PA8472101A1 (es) Combinaciones terapeuticas para la fragilidad musculo esquelectica
ECSP993016A (es) Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratoroidea
AR025589A1 (es) Antagonistas de los receptores de vitronectina.
Kazemian et al. The comparison of fixation and cut-out of proximal intramedullary nail and dynamic hip screw therapy in the treatment of stable intertrochanteric fractures of the femur: A retrospective study
DE602005011661D1 (de) Vitamin-d3-analoga zur prävention undbehandlung von knochenerkrankungen
DK1165184T3 (da) Estrogenreceptor-beta antagonisme og knoglesygdomme
Mochocki et al. Ankle arthrodesis with simultaneous lengthening of the lower limb using the Ilizarov fixator
ECSP993020A (es) Terapia de combinacion para la fragilidad musculoesqueletica